Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Phillippe Gabriel Steg"'
Autor:
Karola S. Jering, Brian L. Claggett, Marc A. Pfeffer, Christopher B. Granger, Lars Køber, Eldrin F. Lewis, Aldo P. Maggioni, Douglas L. Mann, John J.V. McMurray, Margaret F. Prescott, Jean L. Rouleau, Scott D. Solomon, Phillippe Gabriel Steg, Dirk von Lewinski, Eugene Braunwald
Publikováno v:
Circulation: Heart Failure. 16
Background: NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a potent predictor of death and heart failure (HF) across multiple populations. We evaluated the prognostic importance of NT-proBNP in patients with acute myocardial infarction (MI)
Autor:
Georg Nickenig, Róbert Gábor Kiss, Zeki Öngen, Matias Nordaby, Uwe Zeymer, Gregory Y.H. Lip, Jurriën M. ten Berg, José Luis Navarro Estrada, Christopher P. Cannon, Ton Oude Ophuis, Corinna Miede, Stefan H. Hohnloser, Phillippe Gabriel Steg, Jonas Oldgren, Orly Leiva, Deepak L. Bhatt
Publikováno v:
EuroIntervention
Zeymer, U, Leiva, O, Hohnloser, S H, Steg, P G, Oldgren, J, Nickenig, G, Kiss, R G, Ongen, Z, Estrada, J N, Ophuis, T O, Lip, G Y H, Nordaby, M, Miede, C, ten Berg, J M, Bhatt, D L & Cannon, C P 2021, ' Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction : A post hoc analysis of the randomised RE-DUAL PCI trial ', EuroIntervention, vol. 17, no. 6, pp. 474-480 . https://doi.org/10.4244/EIJ-D-20-00799
Zeymer, U, Leiva, O, Hohnloser, S H, Steg, P G, Oldgren, J, Nickenig, G, Kiss, R G, Ongen, Z, Estrada, J N, Ophuis, T O, Lip, G Y H, Nordaby, M, Miede, C, ten Berg, J M, Bhatt, D L & Cannon, C P 2021, ' Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction : A post hoc analysis of the randomised RE-DUAL PCI trial ', EuroIntervention, vol. 17, no. 6, pp. 474-480 . https://doi.org/10.4244/EIJ-D-20-00799
Background: Little is known about the optimal antithrombotic therapy in patients with atrial fibrillation undergoing PCI for ST-elevation myocardial infarction (STEMI). Aims: The aim of this study was to investigate the safety and efficacy of dabigat
Autor:
Frank L.J. Visseren, Ynte M. Ruigrok, Jan Westerink, G.J. de Borst, Joseph M. Massaro, Folkert W. Asselbergs, J A N Dorresteijn, Y. van der Graaf, C.C. Van 'T Klooster, Deepak L. Bhatt, Phillippe Gabriel Steg
Publikováno v:
International journal of cardiology, 325, 140-148. Elsevier Ireland Ltd
Background Existing cardiovascular risk scores for patients with established cardiovascular disease (CVD) estimate residual risk of recurrent major cardiovascular events (MACE). The aim of the current study is to develop and externally validate a pre
Autor:
R Busch, E.A Brinton, Lixia Jiao, Terry A. Jacobson, Christie M. Ballantyne, Michael Miller, Ralph T. Doyle, Deepak L. Bhatt, S.B Ketchum, Rebecca A. Juliano, J.C. Tardif, C Granowitz, Phillippe Gabriel Steg
Publikováno v:
Canadian Journal of Cardiology. 37:S87-S88
Autor:
E.A Brinton, Stuart J. Pocock, C Granowitz, Christie M. Ballantyne, John Gregson, Lixia Jiao, Rebecca A. Juliano, J.C. Tardif, Ralph T. Doyle, Phillippe Gabriel Steg, Michael Miller, S.B Ketchum, Deepak L. Bhatt, Terry A. Jacobson
Publikováno v:
European Heart Journal. 41
Background REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial), a study of 8,179 randomized statin-treated patients with elevated triglycerides (TG) and increased cardiovascular (CV) risk followed for a median of 4.
Autor:
Emmanuelle Vidal-Petiot, Joane Matta, Marie Zins, Pauline Balagny, Justine Frija-Masson, Marcel Goldberg, Phillippe Gabriel Steg, Marie Pia d'Ortho, Emmanuel Wiernik, Céline Ribet
Publikováno v:
European Heart Journal. 41
Background Sleep Disordered Breathing (SDB) is highly prevalent and associated with cardiovascular disease (CVD) but many studies have a limited sample size or uncertain generalizability. Purpose The aim of this study was to obtain contemporary data
Autor:
Rebecca A. Juliano, J.C. Tardif, Christie M. Ballantyne, Terry A. Jacobson, Brian Olshansky, Phillippe Gabriel Steg, E.A Brinton, Cyrus R. Mehta, M. Chung, Lixia Jiao, Michael Miller, Deepak L. Bhatt, Ralph T. Doyle, C Granowitz, S.B Ketchum
Publikováno v:
European Heart Journal. 41
Background REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial), an event-driven trial, randomized 8,179 statin-treated patients with elevated triglycerides (TGs) and increased cardiovascular (CV) risk to icosapent e
Autor:
Phillippe Gabriel Steg, E Van-Ganse, Manon Belhassen, Olivier Hanon, Isabelle Mahé, F. Dalon, Nicholas Danchin, Bruno Falissard, S. Gollety, François-Emery Cotté
Publikováno v:
European Heart Journal. 41
Background In patients with non-valvular atrial fibrillation (NVAF), oral anticoagulants reduce the risk of stroke and systemic embolism, at the expense of an increased risk of bleeding. Purpose To compare the risk of bleeding and sites of bleeding a
Autor:
Shaun G. Goodman, Renato D. Lopes, Johan Wouter Jukema, Harvey D. White, Phillippe Gabriel Steg, Vera Bittner, Robert A. Harrington, Gregory G. Schwartz, Odyssey Outcomes Investigators, Andreas M. Zeiher, Robert Pordy, Michael Szarek, Deepak L. Bhatt, A Dauchy, T Sourdille, Rafael Diaz
Publikováno v:
European Heart Journal. 41
Background Atrial fibrillation (AF) is a marker of risk in patients presenting with acute coronary syndromes (ACS). The potential effect of inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) on the incidence of AF is unknown. Methods Th
Autor:
Gregory Ducrocq, Phillippe Gabriel Steg, Roberto Ferrari, A Gautier, Yedid Elbez, M. Tendera, Kim Fox, J.C. Tardif, Ian Ford
Publikováno v:
European Heart Journal. 41
Introduction Polyvascular disease constitutes a powerful predictor of cardiovascular events, is found in 10 to 15% of chronic coronary syndromes (CCS) patient. Smoking and diabetes mellitus are strongly associated with polyvascular disease. Risk stra